Hydroxychloroquine in nephrology: current status and future directions

Abstract

Hydroxychloroquine is one of the oldest disease-modifying anti-rheumatic drugs in clinical use. The drug interferes with lysosomal activity and antigen presentation, inhibits autophagy, and decreases transcription of pro-inflammatory cytokines. Owing to its immunomodulatory, anti-inflammatory, anti-thrombotic effect, hydroxychloroquine has been an integral part of therapy for systemic lupus erythematosus and lupus nephritis for several decades. The therapeutic versatility of hydroxychloroquine has led to repurposing it for other clinical conditions, with recent studies showing reduction in proteinuria in IgA nephropathy. Research is also underway to investigate the efficacy of hydroxychloroquine in primary membranous nephropathy, Alport’s syndrome, systemic vasculitis, anti-GBM disease, acute kidney injury and for cardiovascular risk reduction in chronic kidney disease. Hydroxychloroquine is well-tolerated, inexpensive, and widely available and therefore, should its indications expand in the future, it would certainly be welcomed. However, clinicians should be aware of the risk of irreversible and progressive retinal toxicity and rarely, cardiomyopathy. Monitoring hydroxychloroquine levels in blood appears to be a promising tool to evaluate compliance, individualize the dose and reduce the risk of retinal toxicity, although this is not yet standard clinical practice. In this review, we discuss the existing knowledge regarding the mechanism of action of hydroxychloroquine, its utility in lupus nephritis and other kidney diseases, the main adverse effects and the evidence gaps that need to be addressed in future research. Graphical abstract Created with Biorender.com. HCQ, hydroxychloroquine; GBM, glomerular basement membrane; mDC, myeloid dendritic cell; MHC, major histocompatibility complex; TLR, toll-like receptor

Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps

“…HCQ is a key anchor drug in SLE: it improves overall survival [5], reduces the risk of all flares [6] and renal flares [7], improves the response to induction therapies in lupus nephritis [5], retards irreversible organ damage [8], especially cardiovascular damage, and reduces thrombosis in patients with associated antiphospholipid syndrome [9]. International guidelines from the European Alliance of Associations for Rheumatology (EULAR), the American College of Rheumatology (ACR) and the Kidney Disease Improving Global Outcomes (KDIGO) universally recommend the use of HCQ in all patients with SLE unless there are contraindications or side effects [10,11].…”

Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis?

“…Hydroxychloroquine, an antimalarial drug, is the oldest disease-modifying anti-rheumatic drug and has been part of SLE therapy and lupus nephritis for decades [ 223 ]. Its complex mechanism of action includes interference with phagocytosis, antibody production and the selective presentation of self-antigens, and bro blocks monocyte and T lymphocyte proliferation and reduces the production of the cytokines TNF-α, IL-6, IL-17, IFN-alpha and gamma [ 221 ].…”